ESMO 2022 Conference Coverage
Lecture Summary - ESMO 2022 on the Phase III ERMES Study: FOLFIRI/Cetuximab vs. FOLFIRI/Cetuximab Followed by Cetuximab Alone in 1L Therapy of RAS and BRAF Wild-Type mCRC
By
ESMO 2022 Conference Coverage
FEATURING
Armando Orlandi
By
ESMO 2022 Conference Coverage
FEATURING
Armando Orlandi
Login to view comments.
Click here to Login
GI